Rare Diseases

With the advancement in the rare disease therapy research, choose DelveInsight to help you unveil the potential of advanced therapies in development, explore how pharma and biotech companies are working to address the low prevalence and high outstanding therapeutics needs, and understand the gaps in the market.

Our Services

Competitive Intelligence

Staying abreast of the rapid changes in the healthcare environment is paramount. Through a combination of robust data, and expert opinion and analysis, we provide real-time actionable insights to our partners and enable them to make informed decisions.

Some of our key services include:

  1. Regulatory Assessment
  2. Opinion Analysis
  3. Congress Intelligence
  4. Strategy Assessment
  5. News Assessment

Our competitive intelligence consulting services provide research-based solutions to help you gain a competitive advantage. Our strategy considers the perspectives of customers, suppliers, business competitors, and others. We gather market data from all corners of the industry and transform it into useful information. Our Competitive Intelligence team, composed of analysts, senior analysts, managers, and key opinion leaders (KOLs), provides our partners with the most up-to-date and accurate intelligence available.

Epidemiology Assessment

One of the major challenges drug developers grapple with in the rare diseases area is the dearth in reliable and accurate epidemiology studies. We bridge this gap by conducting in-depth interviews with the key opinion leaders along with exhaustive literature searches in the 7MM [the US, EU4 (Germany, Italy, Spain, France) and the UK, and Japan] geographies. Our patient-based model approach garners insights around the patient journey, helping our partners understand the treatable patient pool for a given rare indication. The in-depth epidemiological assessment will help you to track all the updates regarding the key challenges and unmet needs in the emerging market and how companies are working to tackle the rising prevalence.

  1. 10 Years Forecast
  2. Disease Risk and burden
  3. Risk of disease by segmentation
  4. Patient Segmentation

Epidemiology Insights provides a framework for epidemiological research and understanding of various indications, such as prevalence/incidence and geographic distribution, clinical manifestations, etiology, pathophysiology, severity, and diagnosis. Our in-depth indication epidemiology analysis will assist you in tracking the growth opportunities for rare diseases across various geographies.

Market Forecast

The drug development process is a long and expensive affair and thus, it is imperative for an innovator to understand the market one is getting into.

Key strengths of our models include:

  1. 10 Years Market Forecast
  2. Major Drugs Uptake
  3. Impact of Upcoming Therapies
  4. Current Treatment Practices
  5. Key Cross Competition

Our keen market forecast insights keep clients up to date on recent developments in the healthcare industry and provide an edge in the competitive pharmaceutical market, which further assists them in understanding the granular view of the market and understanding how the market will evolve over the next decade.

Pricing & Reimbursement

For any orphan indication, putting the right price on a drug is extremely challenging given the lack of quality-adjusted life year (QALY) and health technology assessments (HTA), and limited analogs. By understanding the key elements that define the payer’s purchasing decision and the growing focus on value-based pricing, we help our partners develop the optimal pricing strategy that can significantly improve their product's profitability and market share.

We are a truly multidisciplinary team with years of market access, pricing, and reimbursement experience. This enables us to weigh in data and market research advice from payers/KOLs, as well as an understanding of the future environment, and provide future-proof advice.

Indication Prioritization

Unsure which indication to focus on? Is there a bigger market potential in indication A compared to indication B? These are some of the questions innovators grapple with. Given the long duration of drug development, huge capital requirement, and high failure rate, it becomes essential for the players to understand the granularity of this therapy area and how to play in the market.

DelveInsight offers a solution by walking clients through the current and evolving standards of care to comprehensively estimate the correct value and physician/payer’s perspective, helping them in defining the correct target patient populations and investing wisely in lucrative indications.

DelveInsight analysts collaborate with the client team to develop intelligent criteria, create assessment scenarios based on reliable parameters of importance, and define situations as a result of potential successes and failures. Our Indication Prioritization service helps companies create a solid strategy for R&D by understanding future market dynamics through market modeling, unmet medical needs for future understanding of treatment regimens, and so on.

Partner Assessment

Whether in development or commercial activities, companies frequently seek partnerships that can lead to a win-win situation for the parties involved. The prioritizing interests create the inherent challenge of finding another company with similar interests. DelveInsight, with its proprietary partnering methodology and robust network, helps clients navigate through complex torrents of industry collaborations and assists in identifying the right partner(s) for drug development or commercialization. Through an assessment of unmet needs and strategic alignment, and validation of business perspectives, we help scout the right candidates for a potential collaboration. Our partner assessment services also help the client in identifying, monitoring, and evaluating organizational barriers for maintaining a strong market foothold.

Key takeaways from our service include:

  1. Elucidatory description of the field of interest for tracking intelligent leads
  2. Asset and technology evaluation using predefined landscaping parameters
  3. A transparent process with real-time updates allows for an understanding of the progress
  4. Differentiating potential leads' levels of interest for stratified engagement

Customized Services

Along with the syndicated services, we also offer solutions tailor-made to the specific needs of our partners. Our customized offerings are designed to meet your specific research needs. Customer-centric, solution-oriented approach to assisting our client partners in gaining an advantage and amplifying their growth prospects. We believe in adding value to our customers' businesses by accelerating their growth through strategic advisory services that assist in making sound business decisions. Our customized services help in creating opportunistic paths that are strategically aligned with our client's vision.

Some of the key services custom-made for our partners include:

  1. Newsletter-based Landscape Tracking
  2. Clinical Trial Monitoring
  3. Disease Burden & Unmet Needs
  4. Physician/KOL Perception Analysis

Featured Newsletter

PD-1/PD-L1 inhibitors

Cancer immunotherapy which is known to reactivate weakened immune cells of cancer patients, has yielded a great success in recent years. Promising antitumor effects have been demonstrated in several different solid and hematological malignancies by the introduction of PD-1/PDL-1 blockade therapy. There is a growing concern about whether they are comparable as the use of PD-1/PDL-1 inhibitors is increasing in number for the clinical treatment of cancer.

Related Insights

Myotonic Dystrophy Treatment


Myotonic Dystrophy: In Search of Effective Weaponry to Kick Out Toxic RNAs Weakening Muscles

Myotonic dystrophy (DM), known as “the most variable of all diseases found in medicine,” is a multi-systemic genetic dis...

Read Article
Gene Therapy


Gene Therapy: The Next Milestone and Ultimate Option in a Fight Against Complex Diseases

Gene therapy is an experimental technique that introduces functional genes into a patient’s body to counteract or replac...

Read Article
Cutaneous T-cell Lymphoma Treatment


How Will the Emerging Therapies for Cutaneous T-cell Lymphoma Reshuffle The Treatment Landscape?

Cutaneous T-cell lymphoma (CTCLs) characterized by cutaneous infiltration of malignant monoclonal T-lymphocytes is a rar...

Read Article
Hemophilia A Treatment


Roche’s HEMLIBRA: A Game Changer Drug for Hemophilia A Treatment and Hope for Patients

As per Delveinsight’s “Hemophilia A Epidemiology Assessment” report, there were approximately 45,000 hemophilia A cases...

Read Article
Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market


Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar AATD Treatment Market

According to the DelveInsight assessment, the total prevalent patient population of alpha-1 antitrypsin deficiency in th...

Read Article
Cutaneous T-cell Lymphoma Market


What Factors are Shaping the Trends in the Cutaneous T-cell Lymphoma (CTCL) Treatment Market?

Cutaneous T-cell lymphomas (CTCLs) constitute a group of non-Hodgkin lymphomas of the skin. CTCL has an annual age-adjus...

Read Article

Case Study

In-Licensing Opportunity

A large client based in the USA wanted to in-license potential dMTS based drug delivery asset from companies involved in microneedle technology research for delivering therapeutic products.

Asset Prioritization

A mid-sized pharma client was working to develop their asset portfolio and was interested in assessing best possible asset for atrial fibrillation for future development and licensing needs.

Due Diligence

A medium pharmaceutical client with capabilities in novel formulations was involved in a deal with a manufacturing company for commercial-scale manufacturing of the client’s therapies.